Advanced search
Publication Cover
Expert Opinion on Drug Safety Volume 2, 2003 - Issue 3
Submit an article Journal homepage
213
Views
48
CrossRef citations to date
0
Altmetric
Review

Safety of immunisation and adverse events following vaccination against hepatitis B

Philippe Duclos Project Leader, Immunisation Safety Priority Project, Department of Vaccines and Biologicals, Health Technology and Pharmaceuticals, World Health Organization, Geneva, 20 Avenue Appia, CH-1211 Geneva 27, Switzerland. [email protected]
Pages 225-231 | Published online: 03 Mar 2005

Bibliography

  • WORLD HEALTH ORGANIZATION: State of the World's Vaccines and Immunization. World Health Organization, United Nations Children's Fund, and the World Bank. Department of Vaccines and Biologicals, World Health Organization, Morges (2002). ISBN 92 4 154578 X.
  • KANE M: Hepatitis B control through immunisation. In: Viral Hepatitis and Liver Disease. Rizzetto M, Purcell R, Germ n J, Verme G (Eds). Edizioni Minerva Med. Turin. (1997):638–642.
  • KANE M: Status of hepatitis B immunisation programmes in 1998. Vaccine (1998) 16(Suppl.):104–108.
  • CHANG MH, CHEN CJ, LAI MS et al: Universal hepatitis B vaccination in Taiwan and the incidence of hepatocellular carcinoma in children. N Engl. J. Med. (1997) 336:1855–1859.
  • HSU HM, LU CE LEE SC et al: Seroepidemiologic survey for hepatitis B virus infection in Taiwan: the effect of hepatitis B mass immunization. J. Infect. Dis. (1999) 179:367–370.
  • FISHER MA, EKLUND SA, JAMES SA, LIN X: Adverse events associated with hepatitis B vaccine in US children less than six years of age, 1993 and 1994. Ann. Epidemiol (2001) 11:13–21.
  • CLASSEN JB: The timing of immunization affects the development of diabetes in rodents. Autoimmunity (1996) 24:137–145.
  • DELAGE G, SALIT I, PENNIE R, ALARY M, DUVAL B, WARD B: The possible relation between hepatitis B vaccination and chronic fatigue syndrome. Union Med. Can. (1993)122:278–279.
  • DUCLOS PH, HALL A, VAN DAMME P: Public health aspects of hepatitis B vaccination and multiple sclerosis. In: Genes and Viruses in Multiple Sclerosis. Hommes OR, Wekerle H, Clanet M (Eds), Elsevier Science BV, Amsterdam. (2000:135–141.
  • MAX, DOES M, BUFFLER PA, WIENCKE JK: Immunizations and risk of childhood leukemia - preliminary results from the Northern California childhood leukemia study. A poster presented at the American Association for Cancer Research Annual Meeting, San Francisco, April 9 (2002).
  • MAHONEY FJ, KANE M: Hepatitis B Vaccine. In: Vaccines. Plotkin S, Orenstein W (Eds), WB Saunders Company, Philadelphia (1999):158–182.
  • GLOBAL ADVISORY COMMITTEE ON VACCINE SAFETY: Vaccine safety. Wkly Epidemiol Rec. (1999) 41:337–338.
  • GLOBAL ADVISORY COMMITTEE ON VACCINE SAFETY: Causality assessment of adverse events following immunization Wkly Epidemiol Rec. (2001) 76:85–88.
  • HALSEY NA, DUCLOS P, VAN DAMME P, MARGOLIS H: Hepatitis B vaccine and central nervous system demyelinating diseases. Viral Hepatitis Prevention Board. Pediam Infect. Dis. J. (1999) 18:23–24.
  • WAUBANT E, STUVE 0: Suspected mechanisms involved in multiple sclerosis and putative role of hepatitis B vaccine in multiple sclerosis. Commissioned background paper for IOM Immunization Safety Review Committee (2002).
  • •One of three comprehensive reviews dealing with the most important purported adverse events.
  • STRATTON K, ALMARIO D, MCCORMICK M et al.: Hepatitis B vaccine and demyelinating neurological disorders. In: Immunization Safety Review Committee Institute of Medidne. Stratton K, Almario D, McCormick MC (Eds), National Academy Press, Washington, DC (2002).
  • •One of three comprehensive reviews dealing with the most important purported adverse events.
  • STRATTON RS, HOWE CJ, JOHNSTON RB Jr: Adverse events associated with childhood vaccines: evidence bearing on causality. National Academy Press, Washington, DC (1994).
  • •One of three comprehensive reviews dealing with the most important purported adverse events.
  • ZAJAC BA, WEST DJ, MCALEER WJ, SCOLNICK EM: Overview of the clinical studies with hepatitis B vaccine made by recombinant DNA. J. Infect. (1986) 13(Suppl. A):39–45.
  • ANDRE FE: Summary on safety and efficacy data on a yeast-derived hepatitis B vaccine. Am. J. Med. (1989) 87 (Suppl. 3A):39–45.
  • STEVENS CE, TAYLOR PE, TONG MJ et al.: Yeast-recombinant hepatitis B vaccine: efficacy with hepatitis B immune globulin in prevention of perinatal hepatitis B transmission. JAMA (1987) 257:2612–2616.
  • SZMUNESS W, STEVENS CE, HARLEY EJ et al.: Hepatitis B vaccine: demonstration of efficacy in a controlled clinical trial in a high-risk population in the United States. N Engl. J. Med. (1980) 303:833–841.
  • FRANCIS DP, HADLER SC, THOMPSON SE et al: The prevention of hepatitis B with vaccine: report of the Centers for Disease Control multi-center efficacy trial among homosexual men. Ann. Intern. Med. (1982) 97:362–366.
  • LEWIS E, SHINEFIELD HR, WOODRUFF BA et al.: Safety of neonatal hepatitis B vaccine administration. Pediatr. Infect. Dis. J. (2001) 20:1049–1054.
  • NO AUTHORS LISTED: Centers for Diseases Control and Prevention Update: vaccine side effects, adverse reactions, contraindications and precautions. Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR (1996) 455 (RR-12) :1–35.
  • NO AUTHORS LISTED: Report on the working group on the possible relationship between hepatitis B vaccination and the chronic fatigue syndrome. Can. Commun. Dis. Rep. (1993) 19:25–28.
  • WISE RP, KIMINYO KP, SALIVE ME: Hair loss after routine immunizations. JAMA (1997) 278:1176–1178.
  • CLASSEN DC, CLASSEN JB: The timing of pediatric immunization and the risk of insulin-dependent diabetes mellitus. Infect. Dis. Chi]. Pract. (1997) 6:449–454.
  • KARVONEN M, CEPAITIS Z, TUOMILEHTO J: Association between Type I diabetes and Haemophilus irilluenzae Type b vaccination: birth cohort study. Br Med. J. (1999) 318:1169–1172.
  • JEFFERSON T, DEMICHELI V: No evidence that vaccines cause insulin dependent diabetes mellitus. J. Epidemiol Community Health (1998) 52:674–675.
  • INSTITUTE FOR VACCINE SAFETY DIABETES WORKSHOP PANEL: Childhood immunization and Type I diabetes: summary of an Institute for Vaccine Safety Workshop. Pediatr. Infect. Dis. J. (1999) 18:217–222.
  • DESTEFANO F, MULLOOLY JP, OKORO CA et al: Childhood vaccinations, vaccination timing, and risk of Type I diabetes mellitus. Pediatrics (2001) 108:E112.
  • TOUZE E, GOUT 0, VERDIER-TAILLEFER MH,
  • •• LYON-CAEN 0, ALPEROVITCH A: The first episode of central nervous system demyelinization and hepatitis B virus vaccination]. Rev Neural. (Paris) (2000) 156:242-246. French.
  • FOURRIER A, ALPEROVITCH A, TOUZE E, IMBS JL, BEGAUD B: Anti-hepatitis B vaccine and central demyelinating disorders (CDD): the French Data 2002. Presentation to the Immunization Safety Review Committee, US Institute of Medicine, Meeting 5, March 11(2002).
  • STURKENBOOM MC, WOLFSON C, ROULLET E, HEINZLEF 0, ABENHAIM L: Demyelination, multiple sclerosis, and hepatitis B vaccination: a population-based study in the UK P03.018. Neurology A166 April (2000) (Suppl. 3). Abstract.
  • COUSTANS M, BRUNET E DE MARCO 0, LE PAGE E, CHAPERON J, EDAN G: Demyelinating disease and hepatitis B vaccination survey of 735 patients seen at MS clinic. P03.017 Neurology A165 April (2000) (Suppl. 3). Abstract.
  • CONFAVREUX C, SUISSA S, SADDIER P, BOURDES V, VUKUSIC S: Vaccinations and the risk of relapse in multiple sclerosis. Vaccines in Multiple Sclerosis Study Group. N Engl. j Med. (2001) 344:319–326.
  • ZIPP F, WEIL JG, EINHAUPL KM: No increase in demyelinating diseases after hepatitis B vaccination. Nat. Med. (1999) 5:964–965.
  • SAD OVNICK AD, SCHEIFELE DW: School-based hepatitis B vaccination programme and adolescent multiple sclerosis. Lancet (2000) 355:549–550.
  • ASCHERIO A, ZHANG SM, HERNAN MA et al.: Hepatitis B vaccination and the risk of multiple sclerosis. N Engl. j Med. (2001) 344:327–332.
  • DE STEFANO F AND THE VACCINE SAFETY DATALINK TEAM: Hepatitis B vaccine central nervous system demyelinating disease in adults. Presentation slides Immunization Safety Review Committee, Institute of Medicine, Meeting 5, March 11(2002).
  • GLOBAL ADVISORY COMMITTEE ON VACCINE SAFETY: Global advisory committee on vaccine safety, 20-21 June 2002. Wkly Epidemic] Rec. (2002) 77:389–394.
  • •• Substantially brief meeting highlights,which are accessible on the WHO website.
  • SHAW FE Jr, GRAHAM DJ, GUESS HA et al.: Postmarketing surveillance for neurologic adverse events reported after hepatitis vaccination: experience of the first three years. Am. j Epidemic] (1988) 127:337–352.
  • HERROELEN L, DE KEYSER J, EBINGER G: Central nervous system demyelination after immunization with recombinant hepatitis B vaccine. Lancet (1991) 338:1174–1175.
  • MAHASSIN F, ALGAYRES JP, VALMARY J et al.: [Acute myelitis after vaccination against hepatitis 13]. Presse Med. (1993) 22:1997-1998. French.
  • TREVISANI F, GATTINARA GC, CARACENI P et al.: Transverse myelitis following hepatitis B vaccination. j Hepatol (1993) 19:317–318.
  • NADLER JP: Multiple sclerosis and hepatitis B vaccination. OM. Infect. Dis. (1993) 17:928–929.
  • TARTAGLINO LM, HEIMAN-PATTERSON T, FRIEDMAN DP, FLANDERS AE: MR imaging in a case of postvaccination myelitis. Am. Soc. Neuroradiol (1995) 16:581–582.
  • KONSTANTINOU D, PASCHALIS C, MARAZIOTIS T, DIMOPOULOS P, BASSARIS H, SKOUTELIS A: Two episodes of leukoencephalitis associated with recombinant hepatitis B vaccination in a single patient. OM. Infect. Dis. (2001) 33:1772–1773.
  • CENTERS FOR DISEASES CONTROL AND PREVENTION: Hepatitis B virus: a comprehensive strategy for eliminating transmission in the United States through universal childhood vaccination. Recommendations of the Immunization Practices Advisory Committee (ACIP). MMWR (1991) 40(RR-13):1–25.
  • DOCKERTY JD, SKEGG DCG, ELWOOD JM, HERBISON GP, BECROFT DMO, LEWIS ME: Infection, vaccinations, and the risk of childhood leukaemia. Br. j Cancer (1999) 80(9):1483–1489.
  • CHERIN P, LAFORET P, GHERARDI RK et al: [Macrophagic myofasciitis: description and etiopathogenic hypothesis. Study and Research Group on Acquired and Disimmunity Related Muscular Diseases (GERMAAD) of the French Association Against Myopathies (AFM11. French. Rev Med. Interne (1999) 20:483–489.
  • AUTHIER FJ, CHERIN P, CREANGE A, BONNOTTE B. FERRER X, ABDELMOUMNI A et al: Central nervous system disease in patients with macrophagic myofasciitis. Brain (2001) 124:974–983.
  • GHERARDI RK, COQUET M, CHERIN P et al.: Macrophagic myofasciitis lesions assess long-term persistence of vaccine-derived aluminium hydroxide in muscle. Brain (2001) 124:1821–1831.
  • GLOBAL VACCINE SAFETY ADVISORY COMMITTEE: Macrophagic myofasciitis and aluminium-containing vaccines. Wkly Epidemic] Rec. (1999) 41:338–340.
  • FREED GL, ANDREAE MC, COWAN AE, KATZ SL: The process of public policy formulation: the case of thimerosal in vaccines. Pediatrics (2002) 109:1153–1159.
  • PICHICHERO ME, CERNICHIARI E, LOPRIATO J, TREANOR J: Mercury concentrations and metabolism in infants receiving vaccines containing thiomersal: a descriptive study. Lancet (2002) 360:1737–1741.

Website

  • http://www.agmed.sante.gouv.fr/htm/10/ filcoprs/021101.htm NO AUTHORS LISTED: Vaccination contre l'hépatite B. Communiqué de presse. Agence Francaise de sécurité sanitaire des produits de sante. November 14 (2002). Affiliation

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.